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ABSTRACT
We investigated the relationship between maternal HIV status and uptake of the full series of three doses of
diphtheria-tetanus-pertussis containing vaccines (DTP3) in sub-Saharan African children. We used data
obtained from demographic and health surveys conducted in sub-Saharan Africa. We conducted meta-
analysis and calculated pooled odds ratios (OR) for the association between maternal HIV status and DTP3
vaccination status for each country. A total of 4,187 out of 5,537 children of women living with HIV received
DTP3 (75.6%), compared to 71,290 of 113,513 (62.8%) children of HIV negative women. National DTP3
coverage among children of HIV-positive women varied between 24% and 96% while among children of HIV
negative women it was between 26% and 92%. Overall pooled result showed no signiﬁcant difference in
DTP3 coverage between the two groups (OR D 1.05; 95% conﬁdence interval 0.91 – 1.22), with statistically
signiﬁcant heterogeneity (Chi2 D 91.63, PD 0.000, I2 D 71.6%). There was no signiﬁcant association between
DTP3 coverage and maternal HIV status in sub-Saharan Africa. However, DTP3 coverage for both HIV-
exposed and non-exposed children were below the required target. Meta-regression revealed no signiﬁcant
association between DTP3 coverage and country characteristics (e.g. HIV prevalence among women,
antiretroviral therapy coverage, gross domestic product per capita, human development index, adult literacy
rate and sub-region). Improved prevention of mother-to-child transmission services might have contributed
to some extent to the higher DTP3 vaccination coverage among the HIV-exposed children. There is also
need to address barriers impeding uptake of vaccination among HIV-exposed and non-exposed children.
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Introduction
Human immunodeﬁciency virus (HIV) infection remains a
major public health challenge and a foremost cause of disabil-
ity-adjusted life years in sub-Saharan Africa.1,2 Sub-Saharan
Africa accounts for about 75% of global burden of HIV.3,4 It is
estimated that about 1.5 million HIV-infected children live in
sub-Saharan African countries and these countries also account
for the highest burden of vaccine-preventable diseases.4,5
Vaccination has been demonstrated to be a cost-effective
and beneﬁcial public health intervention in protecting chil-
dren.6 Vaccination is essential in HIV-infected individuals
because of their increased risk of developing various infec-
tious diseases due to defective immune system.7 Unfortu-
nately, the coverage of routine vaccinations for children in
many African countries is still low and inadequate to meet
the Global Vaccine Action Plan (GVAP) targets.8-10 Studies
have also shown that HIV-exposed and infected children
have signiﬁcant increase risk of morbidity and mortality
from various vaccine-preventable diseases when compared
with HIV-unexposed and uninfected children.11,12 The low
vaccination coverage may result in increased susceptibility
to infection by various vaccine-preventable diseases among
the infants of women living with HIV.
Exploring the effect of maternal HIV status on childhood vac-
cination among children in sub-Saharan Africa is critical to
inform vaccine-preventable diseases prevention strategy. A study
on vaccination coverage in HIV-infected patients shows that
patients with given indication for speciﬁc vaccination have better
vaccination coverage, however, adherence to vaccination guide-
lines is not likely to be a determinant for vaccination among the
HIV-infected patients.13 Knowledge gap in research ﬁndings with
respect to the coverage of childhood vaccination and the impact
of maternal HIV status among children necessitate the need to
conduct a study to provide the needed evidence.13
This study examined the vaccination coverage of the three
doses of diphtheria-tetanus-pertussis containing vaccines
(DTP3) among children with respect to the maternal HIV sta-
tus. The study also assessed the relationship between various
country-level characteristics and the coverage of DTP3 among
sub-Saharan African children by pooling available survey data
Results
Description of included countries
This study included only 27 countries based on the availability
of the required demographic and health surveys (DHS) HIV
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and immunisation data sets. The surveys were conducted
between 2003 and 2016 in the included countries. The years
2013 and 2014 had the highest number of surveys totalling ﬁve
each. The included countries, year of survey, coverage of antire-
troviral drugs use during prevention of mother-to-child trans-
mission (PMTCT), HIV prevalence in female, gross domestic
product (GDP) per capital, human development index (HDI),
adult literacy rate and the sample sizes are shown in Table 1. A
total number of 119,050 respondents were included in this
study. A total of 4,187 out of 5,537 (75.6%) children of mothers
living with HIV received DTP3, compared to 71,290 out of
113,513 (62.8%) children of HIV negative mothers.
The percentage coverage of pregnant women who received
antiretroviral drugs for PMTCT varied from 35% in Mali to
96% in Namibia. The HIV prevalence among female aged
15–49 years old widely ranged from 0.5% in Niger to 34.7% in
Swaziland. Among the 27 countries, two are upper
middle-income countries (Gabon and Namibia), eight are
lower middle-income countries (Angola, Cameroun, Cote
d’Ivoire, Ghana, Kenya, Senegal, Swaziland and Zambia) and
the rest are low-income countries. Adult literacy rate ranged
from 15.5% in Niger to 88.7% in Zimbabwe. The DTP3 cover-
age among the children of HIV positive mothers varied
between 24% in Angola and 96% in Rwanda while among the
children of HIV negative mothers it was 26% in Angola and
92% in Rwanda.
Meta-analysis
The odds ratio (OR) and 95% conﬁdence interval (CI) from the
included countries and pooled result are shown in Fig. 1. In
most countries (n D 20), there was no signiﬁcant difference in
the proportion of children of mothers living with HIV that
received DTP3 and the children of HIV negative mothers. In
Sao Tome and Principe, and Malawi, children of mothers living
with HIV were signiﬁcantly less likely to receive DTP3 com-
pared to the HIV negative ones. However, in four countries,
Cameroon, Chad, Ethiopia and Zambia, children of mothers
living with HIV were signiﬁcantly more likely to have received
DTP3. Nonetheless, when the data from the 27 countries were
pooled together using DerSimonian-Laird method, there was
no signiﬁcant difference in DTP3 coverage between the two
groups of women (OR D 1.05; 95% CI 0.91 – 1.22), with statis-
tically signiﬁcant heterogeneity (Chi2 D 91.63 on 26 degree of
freedom, P D 0.000, I2 D 71.6%).
Sub-group analyses
Sub-group analysis was conducted in order to access the effect
of coverage of pregnant women who received antiretroviral
drugs during PMTCT on the pooled estimates. The pooled esti-
mates for countries with low and high coverage were calculated
using the DerSimonian-Laird method. The pooled effect esti-
mates for the low coverage countries was (OR D 1.04; 95% CI
0.90 – 1.21). The calculated pooled effect estimates for the high
coverage countries was (OR D 1.07; 95% CI 0.85 – 1.33)
(Table 2). Sub-group analyses showed that differences between
countries in terms of coverage for antiretroviral drugs, HIV
prevalence, HDI, GDP, adult literacy rate, years of survey and
sub-regions did not explain the heterogeneity of effect estimates
on coverage for DTP3 vaccine among the sub-Saharan Africa
children (Table 2).
Sensitivity analyses
Figure 2 shows leave-one-country out sensitivity analyses used
to assess the stability of the meta-analysis. For the analyses, the
overall estimate was calculated by removing one of the study
countries each time. The changes in the conﬁdence intervals
with this exclusion remain within the 95% conﬁdence interval
for the overall estimate for all the included countries. The anal-
yses show that no one country survey had an undue inﬂuence
on the estimate of the association between maternal HIV status
and DTP3 uptake. The outcome of these sensitivity analyses
indicated the stability of the result.
Meta-regression analysis
Meta-regression analysis was performed to explore factors that
might account for heterogeneity with respect to the country-
level characteristics. We found that the coverage of antiretrovi-
ral drugs use during PMTCT was not signiﬁcantly associated
with the childhood DTP3 vaccination coverage (p D 0.543).
Likewise other characteristics were not signiﬁcantly associated
with the DTP3 coverage except the sample size (p D 0.020)
(Table 2).
Meta-regression plot of the natural logarithm of the odds
ratio of DTP3 coverage regressed against the coverage of preg-
nant women who received antiretroviral drugs for PMTCT in
each country (Fig. 3). The circles represent a country and the
size of each circle mirrors the effect of that country on the model.
Although there was no signiﬁcant relationship between natural
logarithm of the odds ratio of DTP3 coverage and the coverage
of pregnant women who received antiretroviral drugs, however,
the plot shows that the DTP3 coverage slightly increases as
PMTCT coverage increases (b D 1.00, 95% Cl 0.99 – 1.01, p D
0.543) (Fig. 3). Fig. 4 also shows a bubble plot of DTP3 coverage
slightly reducing as HIV prevalence increases.
Discussion
The overall ﬁndings of the meta-analysis involving data from
27 sub-Saharan African countries showed that there is no sig-
niﬁcant difference in the DTP3 coverage among the infants of
women living with HIV and those who are not HIV-infected.
The ﬁndings from this socio-ecological study shows that there
is low coverage of DTP3 vaccination among the HIV-exposed
children, however, the DTP3 coverage among this group of
children is higher than the HIV non-exposed children.
Studies by Eley and Seste et al. show that HIV-infected and
HIV-exposed uninfected ..children are at risk for low immuni-
sation coverage14,15 while another study shows that the children
of women living with HIV actually had more than two-fold
likelihood of been under-immunised than the children of
mothers who are not HIV-infected.16 A Nigerien study shows
that children of HIV-positive women were less likely to receive
second and third doses of DTP-containing vaccines while
another study conducted in South Africa shows that HIV-
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exposed children are also less likely to complete the uptake of
routine childhood vaccinations in comparison with the chil-
dren of HIV-negative women.9,17 These African studies were
conducted in rural and urban poor communities in Uganda,
South Africa, Zambia and Niger with small sample sizes. Most
of these studies were conducted prior to the era of widespread
PMTCT programmes in Africa. This period witnessed unneces-
sary delays in implementing treatment policies, non-integration
of services, Acquired Immunodeﬁciency Syndrome (AIDS)
denialism views, lack of political will, widespread stigma and
discrimination.17,18 There were also issues of weak health sys-
tem and inadequate information about immunisation in most
of the African countries at the time.9,18,19
It is worthy to note that the meta-regression analytic ﬁnd-
ings were not signiﬁcant for most of the country characteristics
apart from the sample size for individual country but the bub-
ble plots show certain patterns that may explain some of the
ﬁndings of the meta-analysis. DHS are large size cross sectional
surveys and likely to have signiﬁcant relationship with DTP3
coverage, however, the survey sample sizes do not have direct
policy implication on the country DTP3 coverage. Meta-regres-
sion plot shows that DTP3 coverage slightly increases as the
coverage of the pregnant women who received antiretroviral
drugs for PMTCT increases (Fig. 4). Likewise the DTP3 cover-
age slightly reduces as the adult female HIV prevalence
increases. Coverage of antiretroviral drugs for PMTCT and
HIV prevalence for female are both important PMTCT indica-
tors and their performance might be contributory to the slight
edge in DTP3 coverage recorded by the HIV-exposed children
and explains the result of the meta-analysis.
The included DHS were mostly conducted post-2009 after
the launch “Global Plan towards the elimination of new HIV
infections among children by 2015 and keeping their mothers
alive”. Global Plan has the goal of reducing new HIV infections
in children, decreasing ﬁnal mother-to-child transmission rate
of HIV infection and increasing the coverage of antiretroviral
therapy in mothers and children.19,20 The integration of
PMTCT services into a broad-based maternal, newborn, and
child health services in many African countries in recent years
has improved the quality and coverage of mother-child pair
care support given to women living with HIV during the post-
Figure 1. Forest plot showing the association between maternal HIV status and
DTP3 coverage in 27 sub-Saharan Africa countries.
Table 2. Sub-group analysis and univariate meta-regression analysis results.
Univariate meta-
regression
Characteristics No of studies Subgroup odds ratio 95% CI I-squared b # 95% CI
Year of survey 0.97 0.92,1.02
2003-2010 5 1.1 0.9, 1.2 87.4*
2011–2016 22 1.0 0.9, 1.2 64.8*
HIV prevalence female 1.00 0.98, 1.02
Low 20 1.1 0.9, 1.3 65.4*
High 6 1.0 0.8, 1.4 84.2*
Pregnant women who receive anti-retroviral (%) 1.00 1.00, 1.01
Low 12 1.0 0.9, 1.2 17.9
High 12 1.1 0.9, 1.3 76.7*
Gross domestic product per capita (US$) 1.00 1.00, 1.00
Low 9 1.1 0.9, 1.3 72.3*
Middle 18 1.0 0.8, 1.3 73.5*
Human development index 0.83 0.10, 6.86
Low 21 1.0 0.9, 1.2 70.1*
Medium 6 1.1 0.9, 1.2 72.7*
Adult literacy rate 1.00 0.99, 1.01
Low 11 1.1 0.8, 1.5 73.4*
High 16 1.0 0.9, 1.2 71.8*
Regions 1.01 0.83, 1.23
Western Africa 13 1.0 0.8, 1.2 51.5*
Central/Eastern Africa 7 1.2 0.9, 1.7 79.5*
Southern Africa 7 1.0 0.8, 1.3 82.5*
Size 1.00* 1.00, 1.00
Smaller studies 20 1.0 0.9, 1.1 44.3*
Larger studies 7 1.4 1.0, 1.9 81.0*
p < 0.05. #b- Beta coefﬁcient.
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delivery and breastfeeding periods. There was a dramatic
increase of about ﬁve folds in the percentage of mothers or
infants on antiretroviral therapy during breastfeeding period
from 2009 to 2013.21 The mother-child pairs are now seen
together and this gives easier access for early infant diagnosis,
scheduled immunisation, timely initiation of antiretroviral
treatment, cotrimoxazole prophylaxis etc.22 As shown by the
ﬁndings of the meta-analysis and meta-regression, all these
interventions targeted at the women living with HIV and their
children has not yielded signiﬁcant difference in terms of vacci-
nation coverage among this group. It is expected that HIV-
exposed children level of DTP3 coverage would be signiﬁcantly
higher especially with frequent routine clinic visit and sched-
uled immunisation. However, the reality on ground shows that
the mothers and care-givers of the HIV-exposed children are
faced with various challenges such as poor socioeconomic sta-
tus, stigma, discrimination especially at community level, poor
awareness of immunisation beneﬁts and negative attitudes of
healthcare workers.15,16,21,22 Just as the case with the general
population, low coverage of vaccination in HIV-exposed chil-
dren could also be as a result of various barriers that emanated
from the national healthcare system, healthcare providers and
caregivers.23
As of 2016, Nigeria, Central African Republic, Niger, Chad,
South Sudan, Democratic Republic of Congo, Mozambique,
Madagascar, Uganda, Kenya, Somalia and Ethiopia were
among the seriously challenged countries that needed Global
Alliance for Vaccines and Immunisation (GAVI) support to
meet up with their national targets for immunisation.24 The
GVAP goal of achieving nationwide DTP3 vaccination cover-
age of at least 90% was not achieved in many of the included
countries at the time of their individual surveys.10 Only
Rwanda achieved DTP3 uptake of more than 90% for the chil-
dren of both HIV-seropositive and –seronegative mothers. At
the time of their individual surveys, Angola, Chad, Congo
Democratic Republic, Gabon, Guinea and Ethiopia recorded
less than 50% coverage either for one or both of the two groups.
DTP3 coverage been the proxy indicator of performance of the
Figure 2. A plot showing the inﬂuence of each country on the overall pooled result using "leave-one-country-out" sensitivity analysis.
Figure 3. showing the association between natural logarithm of the odds ratio for
DTP3 coverage and coverage of women who received anti-retroviral drugs for
PMTCT in each included country.
Figure 4. showing the association between natural logarithm of the odds ratio for
DTP3 coverage and adult female HIV prevalence in each included country.
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national immunisation programmes, is relatively low in sub-
Saharan Africa recording just 74% by the end of 2016.25
Efforts should be made to remove the barriers of vaccination
uptake for the HIV-exposed and non-exposed children.18,21
Implementing public health interventions such as having home
visits speciﬁcally to identify under-vaccinated or non-vacci-
nated children and regular immunisation outreach together
with giving household incentives will help in improving the
DTP3 coverage. This on the long run will translate to having a
successful national immunisation programme. Social determi-
nants could help in transforming the DTP3 uptake irrespective
of maternal HIV status by exploring the behavioural pattern of
individuals and communities via well-structured interven-
tions.26 Interventions like integration of immunisation activi-
ties into various existing public healthcare programmes such as
maternal and child health, antenatal care, PMTCT, antiretrovi-
ral treatment, HIV counselling and testing, and women
empowerment programmes will go a long way to improve
DTP3 coverage.27 Improving DTP3 coverage among HIV-
exposed and non-exposed children especially those living in the
rural and urban poor areas requires a multidimensional collab-
oration.22,23 This entails vaccinating eligible children at every
opportunity, address community stigma, mapping out low-cov-
erage areas localities, community mobilisation and referral for
immunisation.22,28
Limitations and strengths
Conducting this meta-analysis permits the synthesis of ﬁndings
and allows comparison across numerous studies.29 DHS being
a nationally represented survey has a lot of advantages over pri-
mary studies that are limited to just certain geographical loca-
tions. This study has several limitations such as non-inclusion
of data from South Africa and Nigeria that are the two coun-
tries with the largest population of women living with HIV and
HIV-infected children. The two countries were excluded due to
lack of DHS HIV dataset. As an ecological study with cross-sec-
tional design and likeness of ecological fallacy, care must be
taken in attributing causal relationship detected in this
research.
Conclusion
In conclusion, the ﬁndings from this study are valuable infor-
mation that will be beneﬁcial to the public healthcare system in
terms of improving the vaccination coverage of HIV-exposed
children in sub-Saharan Africa. The study indicates that there
is no signiﬁcant difference in the DTP3 coverage among infants
with respect to maternal HIV status in sub-Saharan Africa,
however, there is a signiﬁcant variation in terms of the esti-
mates among the sub-Saharan African countries. The DTP3
coverage for both HIV-exposed children and non-exposed chil-
dren are still below the required target. Improved PMTCT and
maternal child health services across board might have contrib-
uted to the better uptake of DTP3 vaccination among the HIV-
exposed children than the non-exposed children. There is also
the need to address various barriers impeding successful uptake
of vaccination among HIV-exposed and non-exposed children.
A collaborative endeavour is required to improve vaccination
coverage of HIV-exposed children and resultant reduction in
the risk of contracting various vaccine-preventable diseases.
Methods
Data
The study used data obtained from DHS conducted in sub-
Saharan African countries.30 The DHS data are cross-sectional
and population-based representative sample surveys of house-
holds. The sampling frame for each of the survey was made up
of a list of enumeration areas covering the whole country. The
survey involved a two-stage sample design with standardised
questionnaires which were administered to the selected partici-
pants in each country. DHS were implemented by respective
National Ministry of Health or Research/Statistical agencies
with technical support from MEASURE DHS, ICF Interna-
tional, Calverton, Maryland, USA and with funding from vari-
ous development partners such as the Global Fund to Fight
AIDS, Tuberculosis and Malaria, United States Agency for
International Development etc. The included countries were
selected based on the availability of DHS surveys with data on
the uptake of three doses of DTP and HIV test in the mothers
as of November, 2017. Based upon the inclusion criteria, 27
sub-Saharan African countries were included. The included
countries were as follows: Angola, Burkina Faso, Burundi,
Cameroun, Chad, Democratic Republic of the Congo, Cote
d’Ivoire, Ethiopia, Gabon, Gambia, Ghana, Guinea, Kenya,
Lesotho, Liberia, Malawi, Mali, Namibia, Niger, Rwanda, Sao
Tome and Principe, Senegal, Sierra Leone, Swaziland, Togo,
Zambia and Zimbabwe.
Eligible women within the age range of 15–49 years old were
encouraged during the interview to voluntarily test for HIV.
The trained interviewers then collected ﬁnger-prick dried blood
spot specimens for HIV test. The sample collection and analysis
protocol is based on the anonymous linked protocol. This DHS
programme protocol makes room for the merging of results of
the HIV test with other data collected per each respondent’s
individual questionnaires.
Main variable
We recorded the uptake of three doses of diphtheria-tetanus-
pertussis containing vaccines among children aged 12–23
months at any time before the survey; as reported on their vac-
cination cards or by their mothers during interview. The moth-
er’s HIV status was recorded as either HIV seropositive or HIV
seronegative.
Country-level variable
Country-level data were matched within the same time frame
when DHS were conducted using various reports published by
the United Nations Development Programme,31 World Bank32
and Joint United Nations Programme on HIV/AIDS
(UNAIDS).4 The country-level characteristics included in this
study were percentage coverage of pregnant women who
received antiretroviral drugs for PMTCT, HIV prevalence,
childhood vaccination coverage level, gross domestic product
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(GDP) per capita, adult literacy rate, and human development
index (HDI). We divided the country-level variables into low,
medium or high categories in order to provide results that were
more easily interpretable for policy purposes.
These country-level variables were some of the maternal and
developmental factors that are likely determinants of vaccina-
tion coverage especially among HIV-exposed children.16,18 We
expected the study to show the associations between vaccina-
tion coverage and country-level factors by identifying differen-
ces in country characteristics that might be responsible for
variations in the coverage in sub-Saharan Africa.
Ethical consideration
This study used existing DHS data from various countries with
the study data identiﬁer information removed. The surveys
were approved by the Institutional Review Boards of the ICF
International, and the Centers for Disease Control and Preven-
tion, Atlanta, USA and by respective National Ethics Commit-
tees of the included countries. All the study respondents gave
their informed consent for participation with conﬁdentiality
maintained as per the collected information for each of the
participants.
Statistical analysis
Meta-analysis
We calculated odds ratios (OR) for the association between
maternal HIV status and childhood DTP3 vaccination status
for each country. DerSimonian-Laird method (random-effects
model)33 was used to calculate pooled odds ratio across coun-
tries. We evaluated the homogeneity of the results by means of
the Chi-square test and used the I2 to describe the percentage
variation across countries.34-36 We explored substantial hetero-
geneity (I2>50%) by subgroup analysis.
To investigate sources of heterogeneity, sub-group analysis
was conducted using DerSimonian-Laird method. The sub-
groups were designed using the following categories:
i. GDP (low-income:  $1,025; middle-income: $1,026 –
$12,475). GDP middle class consists of both lower-
middle and upper middle classes.
ii. HDI (low: 0.549; medium: 0.550 – 0.770), based on
the classiﬁcation by United Nations Development
Programme.
iii. Coverage of pregnant women who received antiretro-
viral drugs for PMTCT (low:  50.0; high:  50.1).
iv. HIV prevalence aged 15–49 years old (low:  10.0;
high:  10.1). The-cut off of 10.0 was used based on
the range of the prevalence for different countries
included in this study.
v. Adult literacy rate (low:  50.0; high:  50.1).
vi. Sample size (small size if 5000 or large size if 
5001). The cut-off point of 5000 was before it is the
average sample size for the participating countries.
vii. Sub-region (Central/Eastern, Southern and Western
Africa).
viii. Year of survey (2003-2010 and 2011–2016). The cut-
off point for the years of survey was 2010 because 2011
marks the start of the Global Vaccine Action Plan.
We performed leave-one-country-out sensitivity analysis in
order to determine the stability of the results. This analysis
evaluated the inﬂuence of individual country results by
estimating the weighted average odds ratio in the absence of
each country.
Meta-regression analysis
We investigated the impact of various country characteristics
on odds ratio estimates through an inverse-weighted linear
meta-regression analysis. The independent variable was the
natural logarithm of the odds ratio. The explanatory factors
included pre-deﬁned country characteristics such as coverage
of antiretroviral drugs use during PMTCT, HIV prevalence for
females, sample size, sub-region and the calendar year of the
survey. Other included factors were HDI, GDP and the adult
literacy rates.
All the analyses were two sided with p < 0.05 considered
signiﬁcant. Stata 14 (Stata Corp, College Station, TX, USA)
software was used for analysis.37
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